Patients must be able to swallow oral medications without crushing or chewing
Able to swallow oral medications
Patient is able to swallow oral medications
Patients not able to swallow oral medications or with gastrointestinal conditions that may impact absorption of dasatinib
Able to swallow oral medications
Must be able to swallow oral medications
Able to swallow oral medications.
Patients must be able to swallow oral medications
Patient must be able to reliably swallow oral medications
Participants must be able and willing to swallow pills and to absorb oral medications
Subject is able to swallow capsules and is able to take or tolerate oral medications on a continuous basis
Patients must be able to swallow whole capsules and tolerate oral medications
Participants must be able to swallow oral medications
Patient must be able to swallow oral medications
Patients must be able to take oral medications; patients must be able to swallow capsules whole without crushing or altering them in any way
Able to swallow oral formulation of the study agent
Are able to swallow oral medications.
Patients must be able to reliably take and swallow oral medications
Able to swallow oral medications
EXPANSION COHORT ONLY: Able to swallow oral medications
The participant is able to swallow oral medications.
Patients must be able to swallow and tolerate oral medications
Patients must be able to swallow oral medications
Patient must be able to swallow oral medications to be eligible for study enrollment
Patient is able swallow and absorb oral medications
Patients not able to swallow oral medications or with gastrointestinal conditions that may impact absorption of oral medications
Able to swallow oral medications
Able to swallow oral medications
Participants must be able to swallow the oral doses of erlotinib and PPE
Able to swallow oral medications
Ability to swallow oral medications
Unable to swallow oral medications
Unable to receive oral medications
Ability to take oral medications
Ability to swallow oral medications
Ability to take oral medications
Ability to ingest oral medications
Any condition that may impact the subject's ability to swallow oral medications.
Ability to swallow oral medications without difficulty.
Ability to swallow oral medications.
Ability to swallow oral medications
Ability to swallow oral medications.
Patients that unable to swallow oral medications are ineligible
Patients must have the ability to take oral medications
Ability to take oral medications (i.e. no feeding tube and able to swallow whole)
Patients must have the ability to swallow oral medications
Ability to swallow oral medications
Ability to swallow oral medications
Ability to swallow oral medications
Ability to swallow oral medications
oral
oral
Ability to swallow oral medications
Ability to swallow oral medications
Ability to swallow oral medications
Patients unable to swallow oral medications or with pre-existing gastrointestinal disorders that might interfere with proper absorption of oral drugs
Subject is unable to reliably take oral medications
Unable to receive oral medications
Ability to swallow oral medications
Ability to take oral medications
Ability to tolerate oral medications
Unable to swallow oral medications or with pre-existing gastrointestinal disorders.
Ability to take oral medications; a gastrostomy tube is allowed
Ability to tolerate oral or enterically-administered medications.
Unable to take oral medications
Unable to receive oral medications
Ability to take oral medications
Patients unable to swallow oral medications
Ability to take oral medications
Ability to swallow oral medications
Ability to take oral medications
Patients unable to swallow oral medications.
Patients unable to swallow oral medications or with pre-existing gastrointestinal disorders that might interfere with proper absorption of oral drugs
Ability to swallow oral medications
Ability to swallow oral medications
Ability to swallow oral medications.
Ability to take oral medications
Ability to swallow oral medications
Ability to take oral medications and willing to record daily adherance to investigational product
Ability to take oral medications
Ability to take oral medications and willing to record daily adherance to investigational product
Ability to tolerate oral medications.
Ability to swallow oral medications;
Ability to swallow oral medications
Patients unable to swallow oral medications
Ability to swallow oral medications
Willingness to take oral medications during the transplantation period
Unable to receive medications oral medications
Patients who are able to tolerate flexible bronchoscopy
Patients who are deemed unable to safely undergo or tolerate flexible bronchoscopy
Patients who are unable to tolerate anesthesia or sedation
Any physical condition that can prevent ability to tolerate oral therapy
were unable to tolerate the prior first-line regimen
There is no upper age limit but the patients must be able to medically tolerate the regimen
Willing to undergo and able to tolerate frequent MRI or CT assessments during the study
Patient is unable to tolerate MRI (foreign body; i.e. pacemaker or other implanted device; claustrophobia; inability to tolerate rectal coil, etcâ€¦)
Inability to tolerate CPI therapy {if already starte
Patients must be able to tolerate apheresis procedure, including placement of temporary apheresis line if required
Tolerate a 15 g ascorbate infusion (screening dose)
Patients that cannot tolerate MRI
Inability to tolerate aspirin, or other forms of anticoagulation, due to bleeding diathesis
Inability to tolerate premedication with dexamethasone
Inability to tolerate prolonged trendelenburg position as deemed by anesthesiology
Subjects must be able to tolerate apheresis procedure, including placement of temporary apheresis line if required
Patients unable to tolerate transrectal ultrasound.
Inability to tolerate intensive chemotherapy (e.g., patients with AML with 20%-30% blasts and TRM ?4).
Known intolerance to steroid therapy (defined as being unable to tolerate at least 20 mg dex/week)
Inability to tolerate prophylactic anti-thrombotic therapy
Subjects must be able to tolerate apheresis procedure, including placement of temporary apheresis line if required
Patients unable to tolerate checkpoint inhibitor therapy
Inability to tolerate at least one modality of diagnostic anatomic imaging, such as CT or MRI
Able to tolerate prone body positioning during radiation therapy
Perceived inability to tolerate diagnostic or therapeutic procedures
Inability to tolerate cyclophosphamide or undergo total body irradiation at the doses specified in the treatment plan
Inability to tolerate thromboprophylaxis (Cohorts B, C, E, F)
Patients who have had prior everolimus but were not able to tolerate a 10 mg daily dose
Co-morbidities precluding patient's ability to tolerate BMT
Inability to tolerate anesthesia
Patients with KPS < 70 and/or unable to tolerate potentially longer treatment times
Inability to take or tolerate enteral medications
Patients who are unable to take or tolerate oral medications on a continuous basis
Unable to tolerate anti-viral and anti-Pneumocystis jirovecii prophylaxis while on pre-phase and remission induction therapy
Tolerate one test dose (15 g) of ascorbate
Patient is able to tolerate apheresis procedure including placement of temporary apheresis catheter if necessary or has prior apheresis product of 50 x 10^6 mononuclear (MNC) cells available for use
Patient must be able to tolerate lying in the prone position with arms extended forward
Must be able to tolerate MRI scan with contrast
COHORT II: Patient must be able to tolerate lying in the prone position with arms extended forward
COHORT II: Must be able to tolerate MRI scan with contrast
Inability to tolerate contrast dye for baseline CT imaging
Inability to tolerate PET and/or MRI
Able to tolerate pre / post - procedure steroid treatment
Inability to tolerate periodic audiologic testing or to understand a language with established scoring for word recognition testing
Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to 4 hrs of total table time.)
Subjects who cannot tolerate oral administration as determined by the Investigator
Patients who cannot tolerate intravesical dosing or intravesical surgical manipulation
Patient unable to tolerate lymphodepletion, low-dose IL-2 and/or IMA202 product
Significant cardiac disease resulting in inability to tolerate IV fluid hydration for cisplatin
Tolerate one test dose (15g) of ascorbate
Ineligible for curative loco regional treatment and have progressed on or did not tolerate approved treatments of Erivedge (vismodegib, also known as GDC 0449) and Odomzo (sonidegib, also known as erismodegib or LDE225) and have progressed on did not tolerate or are unwilling to try other investigational agents
Willing and able to tolerate brain MRI's with contrast
Able to tolerate daily supplementation of calcium and vitamin D
Patients that cannot tolerate MRI
Subject is not an appropriate candidate for, or unable to tolerate, flexible bronchoscopy procedures
Inability to tolerate thromboprophylaxis
Ability to tolerate intensive therapy with vosaroxin 90 mg/m^2 and standard dose of cytarabine as per investigator discretion
Tolerate a 15 g ascorbate infusion (screening dose)
Receiving warfarin therapy and cannot tolerate drug substitution
Able to tolerate intraperitoneal (IP) port placement and IP treatment administration in the opinion of the enrolling investigator
Patient is unable to tolerate placement of a stereotactic head frame
Patients must be considered able to tolerate systemic chemotherapy combined with pelvic radiation therapy, and radical cystectomy
Predicted inability to tolerate standard induction chemotherapy with daunorubicin and cytarabine
Able to tolerate oral therapy
Patients who cannot tolerate intravesical dosing or intravesical surgical manipulation
Unable to tolerate thromboembolic prophylaxis while on the study
Patients who are unable to reliably tolerate and/or receive oral medications
Inability to tolerate transrectal ultrasound (TRUS).
Tolerate one test dose (15 g) of ascorbate
Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (approximately 3 hrs.)
Have a perceived inability to tolerate diagnostic or therapeutic procedures, particularly treatment in radiation isolation
Inability to tolerate thromboprophylaxis
Participants' inability to adhere to or tolerate protocol or study procedures.
Inability to tolerate PO dosing
Patients must be able to tolerate lumbar puncture and/or Ommaya taps
Ability to tolerate FCR based therapy
Inability to tolerate cyclophosphamide or undergo total body irradiation at the doses specified in the treatment plan
Tolerate one test dose (15 g) of ascorbate
Inability to tolerate lying flat on treatment table for greater than 30 minutes
Perceived inability to tolerate diagnostic or therapeutic procedures
Patients that cannot tolerate being scanned for an additional 12 minutes with arms above their head will be excluded.
Patients with demonstrated allergy to TMZ or who are otherwise unable to tolerate TMZ for any reason will be excluded and replaced if needed; patients who are found after enrollment to be unable to tolerate TMZ will not be a candidate for the vaccine despite being previously enrolled and will be removed from the study and replaced
Perceived inability to tolerate diagnostic or therapeutic procedures, particularly treatment in radiation isolation
Patients who cannot tolerate thoracic radiotherapy or targeted therapy
Pts who are medically unfit to tolerate surgery
Patient is able to tolerate being in the MRI scanner for the duration of the study
Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to 5 hours [hrs] of total table time)
Non-surgical candidates, who may be able to undergo resection of selected single, individual lesion, but may not tolerate extensive surgery, may have many co morbidities, may be prone to complications
Any condition that in the opinion of the investigator would cause the subject to be unable to participate or tolerate the protocol regimen
Able to tolerate oral therapy.
Patients that were unable to tolerate at least 1 cycle of an alkylating agent plus corticosteroid (e.g. melphalan + dexamethasone) or alternative prior regimen because of severe adverse events (e.g. hypersensitivity reaction) may be considered after discussion with the study PI/Medical Monitor.
Patients must have measurable contrast-enhancing progressive or recurrent glioblastoma by MRI within 21 days of starting treatment; patient must be able to tolerate MRIs
Inability to tolerate or absorb an oral medication due to any cause, including but not limited to malabsorption syndromes
Must be able to tolerate MRI scan procedure
Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 2 hrs.)
Patients unable to tolerate oral intake by mouth or per enteral feeding tube
Subject is able to tolerate endoscopy
Previously unable to tolerate either supplement due to taste or gastrointestinal (GI) side effects.
Are able to tolerate surgery (i.e., segmentectomy, lobectomy or bilobectomy) as indicated by standard clinical pre-op evaluation, including pulmonary function tests and cardiac evaluation (if indicated)
Able to tolerate high-flow oxygen/air
Able to tolerate enteral drug administration
Inability to tolerate preoperative oral intake
Ability to tolerate thin liquids by mouth at the time of admission
Inability to tolerate oral or enteral medication
Able to tolerate prone position and breath hold during CT simulation
Patients must be able to tolerate lumbar puncture and/or Ommaya taps
Be able to tolerate topical application of phenylephrine to the oral mucosa
Patients unable to tolerate discontinued use of anti-coagulants prior to and during the ablation procedure.
Tolerate sitting in a rocking or nonrocking chair
Patients must be able to tolerate digital breast tomosynthesis and full-field digital mammographic imaging required by protocol
Inability to tolerate sedated upper endoscopy due to cardiopulmonary instability or other
EXCLUSION - PATIENT: Unable to tolerate exam (i.e., secondary to untreatable claustrophobia, positioning constraints/unable to lie prone)
Must be able to tolerate oral medication or have it administered via an Nasogastric tube (NGT) or GT tube
Must be able to tolerate routine oral voriconazole, posaconazole or isavuconazole as fungal prophylaxis therapy
Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (approximately 3 hrs. sonication time)
Subjects who could not tolerate a PI, IMiDs, or a CD38-directed cytolytic antibody are eligible to enroll in the study.
Patient is incontinent of urine or stool (which would make them unable to tolerate lying still for 60 minutes)
Patients unable to tolerate a SPECT/CT 99mTc-SC scan
Are physically unable to tolerate flexible bronchoscopy or moderate sedation as determined by the bronchoscopist
Unable to tolerate sedation due to medical comorbidities
Ability to undergo MR imaging, tolerate breath hold procedures and follow direction during the imaging process
Unable to tolerate MRI without anesthesia
Patients who are unable to tolerate surgery
Inability to tolerate 60 minutes of PET imaging
Unable to tolerate up to 60 min of PET imaging per imaging session
Deemed unable to safely undergo or tolerate flexible bronchoscopy as per institutional guidelines
Unable to tolerate anesthesia or sedation
Able to tolerate MRI
Patients who cannot tolerate the vaginal ultrasound procedure
Claustrophobia or inability to tolerate MRI examination (lay still for approximately 1 hour and hold breath intermittently)
Able to tolerate supine position
Able to tolerate an MRI examination
Unable to tolerate 60 min of PET imaging per imaging session
Inability to tolerate imaging procedure (i.e., remain relatively still for multiple short durations of 3-4 minutes) over a total time of 20 minutes
Contraindication for or inability to tolerate MRI examination
Patients unable to tolerate a SPECT/CT 99mTc-MAA and 99mTc-DTPA scan
Are physically unable to tolerate flexible bronchoscopy or moderate sedation as determined by the bronchoscopist
Inability to tolerate MRI including conditions such as claustrophobia or inability to lay flat for > 45 minutes
Patients who cannot tolerate imaging up to 120 minutes of total imaging (breaks of several minutes between imaging will be available)
Patients must be in adequate general medical health to safely tolerate a craniotomy
Able to eat a full range of solid food and liquids and tolerate seeds/nuts
Must be able to tolerate PET/CT (i.e. not claustrophobic and able to remain supine)
Patients who are able to tolerate flexible bronchoscopy.
Subjects with severe claustrophobia that is unresponsive to oral anxiolytics
History of claustrophobia.
Claustrophobia
MRI MONITORING SUB-STUDY: Claustrophobia (a fear of enclosed spaces)
Difficulty laying supine and still for up to 4 hours in the MRI unit or claustrophobia
Claustrophobia
Severe claustrophobia
Inability to undergo SRS due to claustrophobia
Claustrophobia
Claustrophobia requiring anxiolytics or sedation; or
Inability to undergo breast MRI (e.g. claustrophobia)
Symptomatic claustrophobia
CONTROL (HEALTHY) GROUP: Symptomatic claustrophobia
Symptomatic claustrophobia
History of claustrophobia
Symptomatic claustrophobia
Have a history of severe claustrophobia
Claustrophobia
Subjects with severe claustrophobia unresponsive to oral anxiolytics
Claustrophobia
Claustrophobia
Have severe claustrophobia
Claustrophobia
Subjects with severe claustrophobia unresponsive to oral anxiolytics
Subjects with severe claustrophobia unresponsive to oral anxiolytics
Severe claustrophobia not relieved by oral anxiolytics per institutional standard practice
Known history of severe claustrophobia
Claustrophobia
Unable to undergo MR imaging (e.g. cardiac device, metals, claustrophobia, etc.)
Patients who due to severe claustrophobia cannot tolerate MRI scanning
Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
Uncontrollable claustrophobia
Patients with inability to cooperate for an MRI exam due to claustrophobia or high levels of anxiety
Known history of claustrophobia
Inability to tolerate imaging procedures (e.g. claustrophobia, severe pain)
Claustrophobia
Claustrophobia
Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
Subjects that exhibit noticeable anxiety and/or claustrophobia
Claustrophobia
Claustrophobia
Extreme claustrophobia that precludes MRI scan
Claustrophobia
Known history of severe claustrophobia
Claustrophobia
Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
Severe claustrophobia
Claustrophobia
Participants with severe claustrophobia unresponsive to oral anxiolytics
Subjects with severe claustrophobia unresponsive to oral anxiolytics
Subjects with severe claustrophobia unresponsive to oral anxiolytics
Have a history of severe claustrophobia
NORMAL VOLUNTEERS: Have a history of severe claustrophobia
Inability to tolerate scanning (e.g. - claustrophobia, severe pain)
Ability to take oral medication
Patients must have the ability to swallow oral dosage forms
Ability to receive oral medication
Ability to take oral medication
Patient has the ability to swallow oral medication and keep a pill diary
Ability to take oral medication
Patients must have the ability to swallow oral medication.
Ability to take oral medication
Ability to swallow an oral solid-dosage form of medication
Ability to swallow an oral solid-dosage form of medication
Ability to swallow an oral solid-dosage form of medication
Ability to take oral medication (i.e. no feeding tube)
Must have ability to take oral medication
Ability to swallow oral medication
Ability to swallow study medication
Impaired ability to swallow oral medication
Participant has an impaired ability to swallow oral medication.
Subject has an impaired ability to swallow oral medication.
Ability to swallow oral medication
Patients must have the ability to swallow oral medication.
Ability to take oral medication;
Patients must have the ability to swallow oral medication.
Ability to swallow oral medication
Ability to swallow oral medication
Ability to swallow oral medication
Ability to swallow oral medicines.
Ability to take oral medication (dasatinib must be swallowed whole)
Ability to receive oral medication
Ability to swallow medication
Ability to swallow oral medication
History of gastrointestinal disorder or defect. Impaired ability to swallow oral medication. Persistent diarrhea or malabsorption.
Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption or ability to swallow oral medication
Ability to receive oral medication
Ability to take oral medication.
Ability to swallow oral medication
Ability to take oral medication;
Patients must have the ability to swallow oral medication
Ability to take oral medication
Ability to swallow an oral solid-dosage form of medication
Ability to swallow study medication
Patients ability to swallow oral medication
Ability to swallow abiraterone acetate tablets as a whole
Ability to swallow tablets
Ability to swallow the investigational product tablets.
Patients must have the ability to swallow tablets
Ability to swallow oral tablets without difficulty
Ability to swallow and retain oral tablets
Willing to take abiraterone acetate on an empty stomach, and should be able to swallow tablets whole, without crushing/chewing tablets; must have the ability to swallow, retain, and absorb oral medication
Patients must have the ability to swallow tablets
Ability to swallow and retain oral tablets
Patients must have the ability to swallow tablets
Ability to swallow tablets without difficulty;
Ability to swallow tablets.
Ability to swallow oral tablets
Ability to swallow and tolerate oral tablets
